Animal Health Product Pipeline

Product Pipeline
We are developing a pipeline of prescription drug product candidates and non-prescription products to address unmet needs in animal health. Our pipeline currently includes prescription drug product candidates for eight indications across multiple species, including the treatment of acute diarrhea in dogs and cats, and non-prescription products targeting seven species including foals, adult horses, dairy calves, and other farm/production animals.

Equilevia™, our personalized, premium, proprietary “total gut health” product for equine athletes, is expected to be commercially available later in 2017. The product will be non-prescription.

Canalevia™ is our lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. A human-specific formulation of crofelemer, Mytesi (formerly known as Fulyzaq), was approved by the U.S. Food and Drug Administration, or FDA, in 2012 for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Jaguar has received Minor Use in a Major Species (MUMS) designation for Canalevia for Chemotherapy-Induced Diarrhea (CID) in dogs. We also completed submission of all required major technical sections for the conditional approval application for Canalevia for CID in dogs to the FDA for phased review.

NeonormCalf is our non-prescription product to help dairies and beef farms proactively retain fluid in calves—helping the animals avoid debilitating, dangerous levels of dehydration (learn more). Neonorm is a botanical extract derived from the Croton lechleri tree.

Our product pipeline leverages the data and knowledge our team has gained during the development from human therapeutics into veterinary applications.

Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals.

MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information